Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study.

CONCLUSIONS: cfDNA levels are significantly higher in BRCA1 and BRCA2 mutation carriers compared with non-carriers. This finding, if validated, may facilitate development of early detection breast/ovarian cancer biomarker in high-risk women. PMID: 32280079 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32280079?dopt=Abstract

Source: Cancer Biomarkers - April 15, 2020 Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research